Overview

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Status:
Recruiting

Trial end date:
2022-07-25

Target enrollment:

Participant gender:

Summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborators:

Genentech/Roche
Roche-Genentech

Treatments:

Venetoclax